# Anti-tuberculosis drug–induced hepatotoxicity and associated risk factors among patients with pulmonary tuberculosis at a tertiary care hospital in Thailand

## Metadata
**Authors:** Sarita Mukura, Parinya Ruenwilai
**Journal:** IJID Regions
**Date:** 2025 May 8
**DOI:** [10.1016/j.ijregi.2025.100665](https://doi.org/10.1016/j.ijregi.2025.100665)
**PMID:** 40547509
**PMCID:** PMC12179635
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179635/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC12179635/pdf/main.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179635/pdf/main.pdf)

## Abstract

Anti-tuberculosis drug–induced hepatotoxicity occurred in 42% of patients during intensive tuberculosis therapy.

Slow N-acetyltransferase 2 acetylator genotype was the strongest predictor of hepatotoxicity (adjusted odds ratio 78.2).

Risk factors included age >70 years, underweight body mass index, and current alcohol use.

Most hepatotoxic events occurred within the first month of treatment.

Findings support targeted monitoring and N-acetyltransferase 2 genotyping for high-risk patients.

Keywords: Tuberculosis, Hepatotoxicity, NAT2 acetylator status, Anti-tuberculosis drugs, Pharmacogenetics

### Objectives

First-line anti-tuberculosis (TB) medications are effective for drug-susceptible TB but are commonly associated with hepatotoxicity, which can compromise treatment adherence and contribute to drug resistance. This study aimed to determine the frequency of anti-TB drug–induced hepatotoxicity and identify associated risk factors among patients at Chiang Mai University Hospital.

### Methods

A retrospective cross-sectional study was conducted among patients with drug-susceptible pulmonary TB receiving standard treatment. Liver function tests were monitored biweekly during the first 2 months to detect hepatotoxicity. The risk factors evaluated included body mass index (BMI), age, alcohol use, N-acetyltransferase 2 (NAT2) acetylator status, and concomitant statin use. Adverse drug reactions were assessed by physicians using severity grading. Binary logistic regression and multivariate analysis were performed to identify independent predictors of hepatotoxicity. Adjusted odds ratios (ORs), 95% confidence intervals (CIs), and *P*-values were reported.

### Results

The incidence of hepatotoxicity was 41.97%. The multivariate analysis showed significant associations between hepatotoxicity and the following: age >70 years (OR = 41.72, *P* = 0.001), underweight BMI (OR = 56.48, *P* = 0.001), current alcohol use (OR = 10.95, *P* = 0.001), and slow NAT2 acetylator status (OR = 78.18, *P* = 0.001).

### Conclusions

Hepatotoxicity is a common complication of TB treatment. Older age, low BMI, alcohol use, slow NAT2 genotype, and statin co-administration significantly increase risk. Targeted monitoring and consideration of NAT2 genotyping in high-risk patients may help prevent treatment interruptions and improve clinical outcomes.

## Introduction

Tuberculosis (TB) is a chronic infectious disease caused by the *Mycobacterium tuberculosis complex*, most commonly *M. tuberculosis*, and pathologically characterized by granuloma formation. Although the lungs are the primary site of infection, TB can also affect extrapulmonary organs such as the kidneys, spine, brain, and skin [[1](#bib0001),[2](#bib0002)]. The standard treatment for drug-susceptible TB involves a 6-month regimen, with a 2-month intensive phase using isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by a 4-month continuation phase with isoniazid and rifampicin alone [[3](#bib0003)]. When adhered to properly, this regimen achieves high cure rates [[4](#bib0004)].

However, adverse drug reactions (ADRs), particularly drug-induced hepatotoxicity, pose a significant challenge to treatment adherence and success [[5](#bib0005)]. Hepatotoxicity may manifest clinically with jaundice or be identified through elevated liver enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, or total bilirubin. ALT is more specific for liver injury, whereas AST elevations may reflect injury in other tissues, including muscle or kidney [[6](#bib0006)]. Discontinuation of therapy is recommended if ALT levels exceed three times the upper limit of normal (ULN) in the presence of symptoms or five times ULN without symptoms. Of the first-line anti-TB drugs, pyrazinamide is most frequently associated with hepatotoxicity, followed by isoniazid and rifampicin [[7](#bib0007),[8](#bib0008)].

A large proportion of patients with TB may experience ADRs during treatment. For instance, a prospective cohort study in Brazil reported that over 75% of participants developed at least one ADR, with nearly half exhibiting clinical symptoms and the rest identified through laboratory findings. Up to 15% of patients may interrupt treatment due to ADRs, often within the first 2 months [[9](#bib0009),[10](#bib0010)]. Such interruptions can necessitate alternative, often longer and more toxic, treatment regimens, ultimately impacting treatment adherence and increasing the risk of poor outcomes, including treatment failure and drug resistance [[8](#bib0008)].

Although previous predictive models have focused on unsuccessful TB treatment outcomes—such as mortality, failure, or regimen change [[11](#bib0011)]—they often did not evaluate ADRs specifically. Given the impact of drug tolerability on treatment completion and success, identifying risk factors for TB-related ADRs, particularly, modifiable ones, is critical [[12](#bib0012),[13](#bib0013)].

Anti-TB drug–induced hepatotoxicity (ATDH) is one of the most clinically significant ADRs and associated with increased morbidity and even mortality in 6-12% of patients with TB [[14](#bib0014)]. The risk is compounded by the prolonged and multidrug nature of TB therapy [[15](#bib0015)].

Given the increasing relevance of pharmacogenetics in clinical practice, the N-acetyltransferase 2 (NAT2) genotype has emerged as a key determinant in predicting isoniazid metabolism and hepatotoxic risk. NAT2 polymorphisms affect the acetylation rate of isoniazid, classifying individuals as slow, intermediate, or rapid acetylators. Slow acetylators have higher plasma isoniazid concentrations, which is associated with a significantly greater risk of liver injury. Incorporating NAT2 genotyping into TB management may offer a personalized approach to mitigate drug toxicity.

This study was conducted at Chiang Mai University Hospital in Thailand and aimed to determine the incidence of ATDH and identify associated risk factors in patients receiving standard anti-TB therapy.

## Methods

### Study design and population

This retrospective cross-sectional study was conducted at Chiang Mai University Hospital, a 1400-bed tertiary care academic medical center in northern Thailand that provides comprehensive diagnostic and treatment service for TB. The study population included newly diagnosed patients with drug-susceptible pulmonary TB who initiated standard first-line anti-TB treatment between January 2020 and June 2024.

Eligible participants were identified retrospectively using hospital TB registry data and International Classification of Disease, 10^th^ Revision codes for TB (A15.x). Inclusion criteria consisted of positive TB diagnosis confirmed by sputum smear or molecular testing and initiation of standard treatment, which includes isoniazid, rifampicin, pyrazinamide, and ethambutol during the 2-month intensive phase, followed by isoniazid and rifampicin in the continuation phase.

Patients were excluded if they were receiving antiretroviral therapy, had baseline ALT or AST levels >3× ULN with hepatitis symptoms or >5× ULN without symptoms, or had known chronic viral hepatitis (hepatitis B virus or hepatitis C virus seropositivity).

ADRs, including hepatotoxicity, were assessed by treating physicians and graded according to the Common Terminology Criteria for Adverse Events version 5.0. ALT grading thresholds were additionally cross-validated with World Health Organization criteria: grade 1 (<2.5 × ULN), grade 2 (2.5-5 × ULN), grade 3 (5-10 × ULN), and grade 4 (>10 × ULN) [[16](#bib0016)].

A subset of patients underwent NAT2 genotyping based on sample availability and institutional resources. Genotypes were categorized as slow, intermediate, or rapid acetylators based on established polymorphism profiles [[17](#bib0017),[18](#bib0018)].

Data were analyzed using IBM SPSS Statistics version 12.0. Descriptive statistics summarized patient characteristics. Bivariate comparisons were conducted using chi-square or Fisher’s exact tests for categorical variables and independent t-tests for continuous variables. Variables with *P* <0.05 in univariate analysis were included in multivariate logistic regression to identify independent predictors. Adjusted odds ratios (ORs), 95% confidence intervals (CIs), and *P*-values were reported.

An enrollment flow diagram summarizing inclusion and exclusion criteria is shown in [Figure 1](#fig0001).

### Figure 1.

![Figure 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0276/12179635/2a4c51c16b1a/gr1.jpg)

[View larger image](https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=12179635_gr1.jpg)

Study enrollment diagram. TB, tuberculosis.

This study aims to improve understanding of ATDH risk during TB therapy and contribute to safer treatment strategies for TB patients in high-burden settings.

### Data collection and definitions

Clinical and demographic data were collected retrospectively from medical records using a standardized data extraction form. Information included age, sex, body mass index (BMI), comorbidities (e.g., diabetes mellitus, hypertension, hyperlipidemia, chronic liver disease), alcohol and tobacco use, and use of concomitant medications such as statins. TB diagnostic data—such as sputum smear and molecular test results—and radiographic findings (e.g., cavitation on chest X-ray) were also reviewed.

Liver function tests, including ALT, AST, alkaline phosphatase, and total bilirubin, were monitored biweekly for 2 months following initiation of standard anti-TB therapy. Hepatotoxicity severity was graded according to World Health Organization guidelines, based on elevations of ALT and total bilirubin, categorized as grade 1 (mild) to grade 4 (life-threatening) [[19](#bib0019)].

ADRs, including hepatotoxicity, were assessed by attending physicians based on clinical evaluation and laboratory findings. Causality was attributed to TB medications when no alternative cause was identified. Only ADRs occurring within the first 60 days of therapy were considered in this study, corresponding to the intensive treatment phase.

NAT2 genotyping was conducted in a subset of patients based on the availability of resources, as full testing was limited by economic constraints. Patients who underwent genotyping were categorized as slow, intermediate, or rapid acetylators based on known polymorphisms associated with NAT2 metabolic activity [[20](#bib0020)].

### Statistical analysis

Data were analyzed using IBM SPSS Statistics version 12.0. Descriptive statistics were used to summarize patient characteristics, presented as means with SDs for continuous variables and frequencies with percentages for categorical variables.

Bivariate analysis was first performed using chi-square or Fisher’s exact tests for categorical variables, and independent t-tests for continuous variables to compare characteristics between patients who developed ATDH and those who did not.

Variables with a *P* <0.05 in the univariate analysis were included in the multivariate logistic regression model to identify independent predictors of hepatotoxicity. Adjusted ORs (AORs) with 95% CIs and corresponding *P*-values were reported. Statistical significance was set at *P* <0.05.

Logistic regression was used to assess the association between risk factors and hepatotoxicity. Univariate and multivariate models were performed. Variables for the multivariate model were selected using bootstrapped backward stepwise selection. Model fit and multicollinearity were assessed before final interpretation.

## Results

A total of 567 patients with drug-susceptible TB were included in the analysis at Chiang Mai University Hospital. Of these, 238 (41.97%) patients developed ATDH during the intensive phase of treatment.

### Demographic and clinical characteristics

#### Baseline characteristics

Patients who developed ATDH were generally older, with a mean age of 60.1 ± 18.87 years, compared with 52.2 ± 13.79 years in those without ADR. A higher proportion of cases occurred in patients aged over 70 years (33.2%) ([Table 1](#tbl0001)). Males accounted for 61.3% of ATDH cases.

| Characteristics | Any TB-ADR(n = 238) | No TB-ADR(n = 329) | P-value |
| --- | --- | --- | --- |
| Age (years)<4040-5050-6060-70>70 | 35 (14.7)30 (12.6)44 (18.5)50 (21.0)79 (33.2) | 51 (15.5)67 (20.4)119 (36.2)78 (23.7)14 (4.3) | 0.001 |
| Age (mean ± SD) | 60.10 ± 18.87 | 52.20 ± 13.79 | 0.001 |
| Male sex | 146 (61.34) | 175 (53.19) | 0.059 |
| Body mass index categoryUnderweight (<18.5 kg/m2)Normal (18.5-25 kg/m2)Overweight (>25 kg/m2) | 113 (47.47)106 (44.53)17 (8) | 9 (2.73)307 (93.31)13 (3.96) | 0.001 |
| Cavitation on chest X-ray | 10 (4.20) | 8 (2.43) | 0.235 |
| Sputum smear positive for Acid fast bacilli | 217 (91.17) | 321 (97.56) | 0.845 |
| Sputum positive for molecular testing | 233 (97.89) | 324 (98.48) | 0.604 |
| Diabetes mellitus | 8 (3.36) | 7 (2.13) | 0.330 |
| Hypertension | 10 (4.20) | 3 (0.91) | 0.001 |
| Chronic liver disease | 35 (14.71) | 3 (0.91) | 0.001 |
| Hyperlipidemia | 25 (10.50) | 3 (0.91) | 0.001 |
| Concomitant statin use | 21 (8.82) | 2 (0.61) | 0.001 |
| Alcohol useNeverFormerCurrent | 69 (28.99)58 (24.36)111 (46.64) | 199 (89.67)74 (22.49)56 (11.16) | 0.001 |
| Tobacco useNeverFormerCurrent | 232 (97.47)5 (2.10)1 (0.43) | 32911 | 0.015 |

Table Caption: Baseline demographics of patients with pulmonary TB treated with standard regimen (N = 567).

A strong association was observed between low BMI and hepatotoxicity. Of those with ATDH, 47.5% were underweight, compared with only 2.7% in the non-ADR group. Conversely, patients who were overweight had a lower risk ([Table 1](#tbl0001)).

Chronic liver disease and hyperlipidemia were also more prevalent in the ADR group, affecting 14.7% and 10.5% of patients respectively, compared with <1% in patients without ADR. Statin use was recorded in 8.8% of those with hepatotoxicity vs just 0.6% of controls, highlighting a potential pharmacologic interaction.

Positive acid-fast bacilli smears and polymerase chain reaction testing were common across both groups; however, cavitary lesions on chest X-ray were slightly more common among those who developed hepatotoxicity (4.2% vs 2.4%) ([Table 1](#tbl0001)).

#### Substance use and hepatotoxicity

Current alcohol use was a significant risk factor: 46.6% of patients with ATDH reported current drinking compared with only 11.2% in the control group. Former use was also more common in the ADR group (24.4% vs 22.5%) ([Table 1](#tbl0001)). Smoking was not significantly associated, but former or current smokers were slightly more frequent in the ATDH group.

#### NAT2 acetylator status

Genotyping for NAT2 was performed in a subset of patients (n = 91). Of patients with ADR, 93.87% were slow acetylators, whereas this phenotype was present in only 4.8% of the non-ADR group. Intermediate and rapid acetylators were underrepresented in those who developed hepatotoxicity ([Table 2](#tbl0002)). These findings highlight a strong genetic predisposition to ATDH in slow metabolizers.

| NAT2 acetylator groupa | Any TB-ADR(n = 49) | No TB-ADR(n = 42) | P-value |
| --- | --- | --- | --- |
| SlowIntermediateRapid | 46 (93.87)2 (4.08)1 (2.05) | 2 (4.77)26 (61.90)14 (33.33) | 0.0010.0010.001 |

Table Caption: Distribution of NAT2 acetylator phenotypes by hepatotoxicity status in patients with TB.

#### Severity and timing of hepatotoxicity

The majority of hepatotoxic events were classified as grade 1 (46.2%) or grade 2 (50%), with a small proportion presenting with grade 3 (2.94%) and grade 4 (0.84%) severity ([Table 3](#tbl0003)).

| ADR hepatotoxicity | No. (%) (N = 238) |
| --- | --- |
| Grade 1Grade 2Grade 3Grade 4 | 110 (46.22)119 (50.00)7 (2.94)2 (0.84) |
| Timing of ADR in related to TB treatment<1 weeks1-2 weeks2-3 weeks3-4 weeks>4 weeks | 11 (4.62)62 (26.05)61 (25.63)99 (41.59)5 (2.10) |

Table Caption: Severity grading and timing of hepatotoxicity among patients with anti-tuberculosis drug–induced hepatotoxicity.

Most ATDH cases occurred within the first 3 weeks of TB therapy. Specifically, 26.1% occurred between 1 and 2 weeks, 25.6% during 2-3 weeks, and 41.6% within 3-4 weeks of treatment initiation. Only a small number of cases were observed beyond the first month ([Table 3](#tbl0003)).

#### Predictors of hepatotoxicity: regression analysis and forest plot interpretation

Univariate logistic regression revealed several clinical and genetic variables significantly associated with ATDH. Patients who were underweight (BMI <18.5 kg/m²) had significantly higher odds of hepatotoxicity (OR = 9.61, 95% CI: 1.28-31.1, *P* = 0.001), whereas being overweight was protective (OR = 0.26, 95% CI: 0.11-0.58, *P* = 0.001). Age also influenced risk; patients aged over 70 years had markedly elevated odds (OR = 8.22, 95% CI: 4.03-16.77, *P* = 0.001), whereas those aged 51-60 years had a lower risk (OR = 0.539, *P* = 0.028). Current alcohol consumption was strongly associated with hepatotoxicity (OR = 5.72, 95% CI: 3.75-8.72, *P* = 0.001). In terms of genetic factors, slow NAT2 acetylators had the highest unadjusted odds (OR = 34.93, 95% CI: 8.38-145.59, *P* = 0.001), whereas intermediate and rapid acetylators were significantly protected. Statin use also showed a strong association (OR = 15.82, *P* = 0.001) in the univariate analysis.

In the multivariate logistic regression ([Table 4](#tbl0004)), age over 70 years remained the most significant independent predictor of hepatotoxicity, with an AOR of 41.72 (95% CI: 11.33-153.63, *P* = 0.001). Current alcohol use was independently associated with nearly 11-fold increased odds (AOR = 10.95, 95% CI: 4.73-25.37, *P* = 0.001), although former use was no longer significant after adjustment. In addition, underweight patients (BMI <18.5 kg/m²) had significantly higher odds of developing hepatotoxicity (AOR = 56.48, 95% CI: 8.64-369.21, *P* = 0.001), suggesting that malnutrition is a notable vulnerability factor during TB treatment.

| Variable | Univariate OR (95% CI) | Univariate P-value | Multivariate OR (95% CI) | Multivariate P-value |
| --- | --- | --- | --- | --- |
| Underweight (BMI) | 9.61 (1.28-31.1) | 0.001 | 56.484 (8.641-369.215) | 0.001 |
| Overweight (BMI) | 0.26 (0.11-0.58) | 0.001 | 0.018 (0.003-0.116) | 0.001 |
| Age 40-50 years | 0.652 (0.355-1.199) | 0.169 | 0.659 (0.213-2.037) | 0.469 |
| Age 51-60 years | 0.539 (0.310-0.936) | 0.028 | 0.301 (0.099-0.913) | 0.034 |
| Age 61-70 years | 0.934 (0.535-1.632) | 0.811 | 0.809 (0.282-2.320) | 0.693 |
| Age >70 years | 8.222 (4.031-16.771) | 0.001 | 41.715 (11.327-153.632) | 0.001 |
| Alcohol use: former | 2.26 (1.46-3.51) | 0.001 | 1.003 (0.354-2.841) | 0.996 |
| Alcohol use: current | 5.72 (3.75-8.72) | 0.001 | 10.951 (4.726-25.373) | 0.001 |
| NAT2 slow | 34.93 (8.38-145.59) | 0.001 | 78.181 (14.166-431.464) | 0.001 |
| NAT2 intermediate | 0.117 (0.027-0.498) | 0.004 | 0.035 (0.003-0.430) | 0.009 |
| NAT2 rapid | 0.108 (0.014-0.832) | 0.033 | 0.001 (0.000-0.012) | 0.001 |
| Concomitant statin use | 15.82 (3.67-68.17) | 0.001 | — |   |

Table Caption: Univariate and multivariate analyses of risk factors associated with hepatotoxicity among TB patients treated at Chiang Mai University Hospital.

Notably, NAT2 acetylator phenotype was a strong genetic determinant. Slow acetylators had dramatically increased odds of hepatotoxicity (AOR = 78.18, 95% CI: 14.17-431.46, *P* = 0.001). In contrast, intermediate acetylators (AOR = 0.035, *P* = 0.009) and rapid acetylators (AOR = 0.001, *P* = 0.001) were significantly protected, reinforcing the role of pharmacogenetic variability in drug metabolism and toxicity. Although statin use remained significant in univariate analysis, it was not retained in the final multivariate model, likely due to collinearity with comorbid conditions, such as hyperlipidemia and chronic liver disease.

The forest plot ([Figure 2](#fig0002)) graphically illustrates the multivariate-adjusted ORs on a log scale. Predictors such as slow NAT2 acetylator status, current alcohol use, age over 70 years, and underweight BMI are shown to the right of the reference line (OR = 1), indicating increased risk, whereas intermediate/rapid NAT2 phenotypes and overweight BMI appear to the left, indicating protective associations. The visual clarity of this plot reinforces the strength and direction of each predictor, supporting the regression findings and offering valuable insight into the risk profile of patients undergoing TB treatment.

![Figure 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0276/12179635/b3737eb5b505/gr2.jpg)

[View larger image](https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=12179635_gr2.jpg)

Forest plot of adjusted odds ratios for risk factors associated with anti-TB drug–induced hepatotoxicity at Chiang Mai University Hospital. BMI, body mass index; CI, confidence interval; NAT2, N-acetyltransferase 2; TB, tuberculosis.

## Discussion

This study investigated the risk factors associated with hepatotoxicity in patients with pulmonary TB undergoing standard anti-TB therapy at Chiang Mai University Hospital, using clinical and genetic variables [[21](#bib0021)]. Our analysis highlighted that most hepatotoxic events occurred during the intensive phase of TB treatment, with grade 2 hepatotoxicity being the most common (50%), consistent with previous literature from Singapore and Ethiopia [[14](#bib0014),[22](#bib0022)].

A major finding was the strong association between slow NAT2 acetylator status and hepatotoxicity, where patients with this genotype had significantly elevated odds (multivariate OR: 78.2; 95% CI: 14.2-431.5). This aligns with evidence that slow acetylators metabolize isoniazid less efficiently [[23](#bib0023)], resulting in higher plasma concentrations and an increased risk of liver injury [[24](#bib0024)]. In line with other cohorts, alcohol use, particularly, current drinking, was also identified as an independent risk factor for hepatotoxicity (multivariate OR: 10.95; 95% CI: 4.73-25.37). However, in some regional studies [[25](#bib0025)], this association was not statistically significant for former drinkers, possibly due to differences in drinking patterns across populations.

BMI also played a significant role. Patients classified as underweight were at markedly higher risk (OR: 56.48), whereas patients who were overweight had a protective effect (OR: 0.26). This observation supports previous findings suggesting that malnutrition may impair hepatic resilience against drug-induced toxicity [[26](#bib0026)]. Age was another significant determinant: individuals aged over 70 years had substantially higher risk (OR: 41.7), confirming similar trends in other populations [[27](#bib0027)]. The increased vulnerability of older adults may be attributed to the presence of multiple comorbidities and concurrent medication use [[25](#bib0025)].

Notably, concomitant medication use—especially statins—was also associated with hepatotoxicity, although this could not be included in multivariate models due to limited sample size. This finding echoes data from Brazil [[28](#bib0028)], where polypharmacy, particularly, among individuals who were HIV negative, significantly increased TB-ADR risk.

Regarding the onset of hepatotoxicity, most cases in our cohort occurred between the second and fourth weeks after treatment initiation, aligning with studies from Ethiopia [[29](#bib0029)] and Malaysia [[30](#bib0030)]. This timeframe corresponds with the period before hepatic adaptation to anti-TB drugs develops.

This study integrated genetic and clinical data to identify key predictors of ATDH, yielding findings that are clinically relevant and applicable to resource-limited settings. However, we only analyzed the first hepatotoxic episode and did not assess recurrence or cumulative liver injury. In addition, the sample size for NAT2 genotyping and concomitant medication subtypes was limited, which may have impacted statistical power.

Given the strong association between slow NAT2 acetylator status and hepatotoxicity observed in our cohort (AOR = 78.18, 95% CI: 14.17-431.46), NAT2 genotyping should be considered for patients with clinical risk factors—such as advanced age, underweight BMI, or concomitant medication use—before TB treatment initiation. Identifying slow acetylators early may enable personalized isoniazid dosing, thereby minimizing hepatotoxicity risk and improving treatment safety.

## Conclusion

Our findings affirm that NAT2 slow acetylator status, underweight BMI, older age, alcohol use, and statin use are major risk factors for ATDH. These variables should be considered at treatment initiation, and proactive monitoring or dose adjustments may mitigate the risk of hepatotoxicity. Implementation of pre-treatment NAT2 genotyping in high-risk populations could further enhance the safety of anti-TB therapy by enabling individualized isoniazid dosing, thereby reducing the incidence of severe ADRs and optimizing personalized TB management strategies. Further research with larger, ethnically diverse populations and prospective follow-up is warranted to refine risk prediction models and improve TB treatment safety.

This study has several limitations. First, alcohol intake was not quantified in grams per day due to limited documentation in medical records, which may have influenced the assessment of its role as a risk factor. Second, the findings related to NAT2 acetylator phenotypes may not be generalizable beyond Asian populations because NAT2 polymorphisms vary significantly across ethnic groups. Third, potential sources of bias include selection bias due to convenience sampling and misclassification of ADRs. These were minimized using standardized data extraction protocols and physician adjudication of ADRs.

Future research should explore the clinical utility of NAT2-guided therapy through prospective studies, particularly, to evaluate its role in minimizing hepatotoxicity. In addition, research on the development and implementation of point-of-care NAT2 testing and the inclusion of broader, ethnically diverse populations is warranted to improve the generalizability of findings and optimize personalized TB care.

## Declarations of competing interest

The authors have no competing interests to declare.

## Acknowledgments

### Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### Ethics statement

This study was approved by the Research Ethics Committee of Chiang Mai University Hospital ([study code: MED-2567-0516] and [research ID: 0516]). As a retrospective review of medical records with no direct patient contact, the requirement for informed consent was waived. All procedures were conducted in accordance with the Declaration of Helsinki and institutional ethical standards.

### Acknowledgment

The authors would like to express their sincere gratitude to the staff of Chiang Mai University Hospital and all participants involved in this study. Special thanks are extended to the clinical laboratory and pharmacy teams for their technical support and data collection assistance.

### Author contributions

Sarita Mukura: conceptualization, data collection, data analysis, drafting of the manuscript. Parinya Ruenwilai: study supervision, statistical analysis, interpretation of results, critical revision of the manuscript, and corresponding author responsibilities. Both authors reviewed and approved the final version of the manuscript.

### Disclaimer

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Chiang Mai University or its affiliated institutions.

### Data availability statement

The data supporting the findings of this study are available from the corresponding author upon reasonable request. Due to hospital confidentiality policies and ethical restrictions, the data are not publicly available.

## Associated Data

*This section collects any data citations, data availability statements, or supplementary materials included in this article.*

### Data Availability Statement

The data supporting the findings of this study are available from the corresponding author upon reasonable request. Due to hospital confidentiality policies and ethical restrictions, the data are not publicly available.

### Data Availability Statement

The data supporting the findings of this study are available from the corresponding author upon reasonable request. Due to hospital confidentiality policies and ethical restrictions, the data are not publicly available.

## References

1. Pratt R.H., Manangan L.P., Cummings C.N., Langer AJ. Noncountable tuberculosis case reporting, national tuberculosis surveillance system, United States, 2010–2014. Public Health Rep. 2020;135:18–24. doi: 10.1177/0033354919884302.  [DOI](https://doi.org/10.1177/0033354919884302) | [PMC free article](/articles/PMC7119265/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/31722186/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Public%20Health%20Rep&title=Noncountable%20tuberculosis%20case%20reporting,%20national%20tuberculosis%20surveillance%20system,%20United%20States,%202010%E2%80%932014&author=R.H.%20Pratt&author=L.P.%20Manangan&author=C.N.%20Cummings&author=AJ.%20Langer&volume=135&publication_year=2020&pages=18-24&pmid=31722186&doi=10.1177/0033354919884302&)

2. Riccardi N., Cenderello G., Borroni E., Rutigliani M., Cirillo DM. A case report of mucocutaneous tuberculosis after orthotopic liver transplantation: a challenging diagnosis. BMC Infect Dis. 2018;18:431. doi: 10.1186/s12879-018-3347-7.  [DOI](https://doi.org/10.1186/s12879-018-3347-7) | [PMC free article](/articles/PMC6114782/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/30157783/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMC%20Infect%20Dis&title=A%20case%20report%20of%20mucocutaneous%20tuberculosis%20after%20orthotopic%20liver%20transplantation:%20a%20challenging%20diagnosis&author=N.%20Riccardi&author=G.%20Cenderello&author=E.%20Borroni&author=M.%20Rutigliani&author=DM.%20Cirillo&volume=18&publication_year=2018&pages=431&pmid=30157783&doi=10.1186/s12879-018-3347-7&)

3. Shin H.J., Kwon YS. Treatment of drug susceptible pulmonary tuberculosis. Tuberc Respir Dis (Seoul) 2015;78:161–167. doi: 10.4046/trd.2015.78.3.161.  [DOI](https://doi.org/10.4046/trd.2015.78.3.161) | [PMC free article](/articles/PMC4499581/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/26175767/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Tuberc%20Respir%20Dis%20(Seoul)&title=Treatment%20of%20drug%20susceptible%20pulmonary%20tuberculosis&author=H.J.%20Shin&author=YS.%20Kwon&volume=78&publication_year=2015&pages=161-167&pmid=26175767&doi=10.4046/trd.2015.78.3.161&)

4. Verbeeck R.K., Günther G., Kibuule D., Hunter C., Rennie TW. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. Eur J Clin Pharmacol. 2016;72:905–916. doi: 10.1007/s00228-016-2083-4.  [DOI](https://doi.org/10.1007/s00228-016-2083-4) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/27305904/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Clin%20Pharmacol&title=Optimizing%20treatment%20outcome%20of%20first-line%20anti-tuberculosis%20drugs:%20the%20role%20of%20therapeutic%20drug%20monitoring&author=R.K.%20Verbeeck&author=G.%20G%C3%BCnther&author=D.%20Kibuule&author=C.%20Hunter&author=TW.%20Rennie&volume=72&publication_year=2016&pages=905-916&pmid=27305904&doi=10.1007/s00228-016-2083-4&)

5. Shah H., Yasobant S., Patel J., Bhavsar P., Saha S., Patel Y., et al. Characteristics and contributing factors of adverse drug reactions: an analytical study of patients with tuberculosis receiving treatment under the National TB Program of India. F1000Res. 2022;11:1388. doi: 10.12688/f1000research.125815.2.  [DOI](https://doi.org/10.12688/f1000research.125815.2) | [PMC free article](/articles/PMC11811607/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/39935535/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=F1000Res&title=Characteristics%20and%20contributing%20factors%20of%20adverse%20drug%20reactions:%20an%20analytical%20study%20of%20patients%20with%20tuberculosis%20receiving%20treatment%20under%20the%20National%20TB%20Program%20of%20India&author=H.%20Shah&author=S.%20Yasobant&author=J.%20Patel&author=P.%20Bhavsar&author=S.%20Saha&volume=11&publication_year=2022&pages=1388&pmid=39935535&doi=10.12688/f1000research.125815.2&)

6. Saukkonen J.J., Cohn D.L., Jasmer R.M., Schenker S., Jereb J.A., Nolan C.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–952. doi: 10.1164/rccm.200510-1666ST.  [DOI](https://doi.org/10.1164/rccm.200510-1666ST) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17021358/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Respir%20Crit%20Care%20Med&title=An%20official%20ATS%20statement:%20hepatotoxicity%20of%20antituberculosis%20therapy&author=J.J.%20Saukkonen&author=D.L.%20Cohn&author=R.M.%20Jasmer&author=S.%20Schenker&author=J.A.%20Jereb&volume=174&publication_year=2006&pages=935-952&pmid=17021358&doi=10.1164/rccm.200510-1666ST&)

7. Marzuki O.A., Fauzi A.R., Ayoub S., Kamarul Imran M. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med J. 2008;49:688–693.  [PubMed](https://pubmed.ncbi.nlm.nih.gov/18830542/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Singapore%20Med%20J&title=Prevalence%20and%20risk%20factors%20of%20anti-tuberculosis%20drug-induced%20hepatitis%20in%20Malaysia&author=O.A.%20Marzuki&author=A.R.%20Fauzi&author=S.%20Ayoub&author=M.%20Kamarul%20Imran&volume=49&publication_year=2008&pages=688-693&pmid=18830542&)

8. Yee D., Valiquette C., Pelletier M., Parisien I., Rocher I., Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–1477. doi: 10.1164/rccm.200206-626OC.  [DOI](https://doi.org/10.1164/rccm.200206-626OC) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/12569078/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Respir%20Crit%20Care%20Med&title=Incidence%20of%20serious%20side%20effects%20from%20first-line%20antituberculosis%20drugs%20among%20patients%20treated%20for%20active%20tuberculosis&author=D.%20Yee&author=C.%20Valiquette&author=M.%20Pelletier&author=I.%20Parisien&author=I.%20Rocher&volume=167&publication_year=2003&pages=1472-1477&pmid=12569078&doi=10.1164/rccm.200206-626OC&)

9. Ridolfi F., Amorim G., Peetluk L.S., Haas D.W., Staats C., Araújo-Pereira M., et al. Prediction models for adverse drug reactions during tuberculosis treatment in Brazil. J Infect Dis. 2024;229:813–823. doi: 10.1093/infdis/jiae025.  [DOI](https://doi.org/10.1093/infdis/jiae025) | [PMC free article](/articles/PMC10938211/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/38262629/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Infect%20Dis&title=Prediction%20models%20for%20adverse%20drug%20reactions%20during%20tuberculosis%20treatment%20in%20Brazil&author=F.%20Ridolfi&author=G.%20Amorim&author=L.S.%20Peetluk&author=D.W.%20Haas&author=C.%20Staats&volume=229&publication_year=2024&pages=813-823&pmid=38262629&doi=10.1093/infdis/jiae025&)

10. Breen R.A., Miller R.F., Gorsuch T., Smith C.J., Schwenk A., Holmes W., et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61:791–794. doi: 10.1136/thx.2006.058867.  [DOI](https://doi.org/10.1136/thx.2006.058867) | [PMC free article](/articles/PMC2117099/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/16844730/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Thorax&title=Adverse%20events%20and%20treatment%20interruption%20in%20tuberculosis%20patients%20with%20and%20without%20HIV%20co-infection&author=R.A.%20Breen&author=R.F.%20Miller&author=T.%20Gorsuch&author=C.J.%20Smith&author=A.%20Schwenk&volume=61&publication_year=2006&pages=791-794&pmid=16844730&doi=10.1136/thx.2006.058867&)

11. Peetluk L.S., Rebeiro P.F., Ridolfi F.M., Andrade B.B., Cordeiro-Santos M., Kritski A., et al. A clinical prediction model for unsuccessful pulmonary tuberculosis treatment outcomes. Clin Infect Dis. 2022;74:973–982. doi: 10.1093/cid/ciab598.  [DOI](https://doi.org/10.1093/cid/ciab598) | [PMC free article](/articles/PMC8946703/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/34214166/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&title=A%20clinical%20prediction%20model%20for%20unsuccessful%20pulmonary%20tuberculosis%20treatment%20outcomes&author=L.S.%20Peetluk&author=P.F.%20Rebeiro&author=F.M.%20Ridolfi&author=B.B.%20Andrade&author=M.%20Cordeiro-Santos&volume=74&publication_year=2022&pages=973-982&pmid=34214166&doi=10.1093/cid/ciab598&)

12. Arriaga M.B., Amorim G., Queiroz A.T.L., Rodrigues M.M.S., Araújo-Pereira M., Nogueira B.M.F., et al. Novel stepwise approach to assess representativeness of a large multicenter observational cohort of tuberculosis patients: the example of RePORT Brazil. Int J Infect Dis. 2021;103:110–118. doi: 10.1016/j.ijid.2020.11.140.  [DOI](https://doi.org/10.1016/j.ijid.2020.11.140) | [PMC free article](/articles/PMC7959330/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/33197582/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int%20J%20Infect%20Dis&title=Novel%20stepwise%20approach%20to%20assess%20representativeness%20of%20a%20large%20multicenter%20observational%20cohort%20of%20tuberculosis%20patients:%20the%20example%20of%20RePORT%20Brazil&author=M.B.%20Arriaga&author=G.%20Amorim&author=A.T.L.%20Queiroz&author=M.M.S.%20Rodrigues&author=M.%20Ara%C3%BAjo-Pereira&volume=103&publication_year=2021&pages=110-118&pmid=33197582&doi=10.1016/j.ijid.2020.11.140&)

13. Abbasi M.A., Ahmed N., Suleman A., Zaman H., Tariq S., Anwar S.A., et al. Common risk factors for the development of anti tuberculosis treatment induced hepatotoxicity. J Ayub Med Coll Abbottabad. 2014;26:384–388.  [PubMed](https://pubmed.ncbi.nlm.nih.gov/25671954/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Ayub%20Med%20Coll%20Abbottabad&title=Common%20risk%20factors%20for%20the%20development%20of%20anti%20tuberculosis%20treatment%20induced%20hepatotoxicity&author=M.A.%20Abbasi&author=N.%20Ahmed&author=A.%20Suleman&author=H.%20Zaman&author=S.%20Tariq&volume=26&publication_year=2014&pages=384-388&pmid=25671954&)

14. Molla Y., Wubetu M., Dessie B. Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia. Hepat Med. 2021;13:1–8. doi: 10.2147/HMER.S290542.  [DOI](https://doi.org/10.2147/HMER.S290542) | [PMC free article](/articles/PMC7850419/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/33536799/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Hepat%20Med&title=Anti-tuberculosis%20drug%20induced%20hepatotoxicity%20and%20associated%20factors%20among%20tuberculosis%20patients%20at%20selected%20hospitals,%20Ethiopia&author=Y.%20Molla&author=M.%20Wubetu&author=B.%20Dessie&volume=13&publication_year=2021&pages=1-8&pmid=33536799&doi=10.2147/HMER.S290542&)

15. Maiolini M., Gause S., Taylor J., Steakin T., Shipp G., Lamichhane P., et al. The war against tuberculosis: a review of natural compounds and their derivatives. Molecules. 2020;25:3011. doi: 10.3390/molecules25133011.  [DOI](https://doi.org/10.3390/molecules25133011) | [PMC free article](/articles/PMC7412169/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/32630150/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Molecules&title=The%20war%20against%20tuberculosis:%20a%20review%20of%20natural%20compounds%20and%20their%20derivatives&author=M.%20Maiolini&author=S.%20Gause&author=J.%20Taylor&author=T.%20Steakin&author=G.%20Shipp&volume=25&publication_year=2020&pages=3011&pmid=32630150&doi=10.3390/molecules25133011&)

16. Tostmann A., Boeree M.J., Aarnoutse R.E., de Lange W.C.M., van der Ven AJAM, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192–202. doi: 10.1111/j.1440-1746.2007.05207.x.  [DOI](https://doi.org/10.1111/j.1440-1746.2007.05207.x) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17995946/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Gastroenterol%20Hepatol&title=Antituberculosis%20drug-induced%20hepatotoxicity:%20concise%20up-to-date%20review&author=A.%20Tostmann&author=M.J.%20Boeree&author=R.E.%20Aarnoutse&author=W.C.M.%20de%20Lange&author=AJAM%20van%20der%20Ven&volume=23&publication_year=2008&pages=192-202&pmid=17995946&doi=10.1111/j.1440-1746.2007.05207.x&)

17. Cheli S., Torre A., Schiuma M., Montrasio C., Civati A., Galimberti M., et al. NAT2 slow acetylator phenotype as a significant risk factor for hepatotoxicity caused by antituberculosis drugs: results from a multiethnic nested case-control study. Clin Infect Dis. 2024:ciae583. doi: 10.1093/cid/ciae583.  [DOI](https://doi.org/10.1093/cid/ciae583) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/39727196/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&title=NAT2%20slow%20acetylator%20phenotype%20as%20a%20significant%20risk%20factor%20for%20hepatotoxicity%20caused%20by%20antituberculosis%20drugs:%20results%20from%20a%20multiethnic%20nested%20case-control%20study&author=S.%20Cheli&author=A.%20Torre&author=M.%20Schiuma&author=C.%20Montrasio&author=A.%20Civati&publication_year=2024&pages=ciae583&pmid=39727196&doi=10.1093/cid/ciae583&)

18. McDonagh E.M., Boukouvala S., Aklillu E., Hein D.W., Altman R.B., Klein TE. PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics. 2014;24:409–425. doi: 10.1097/FPC.0000000000000062.  [DOI](https://doi.org/10.1097/FPC.0000000000000062) | [PMC free article](/articles/PMC4109976/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24892773/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenet%20Genomics&title=PharmGKB%20summary:%20very%20important%20pharmacogene%20information%20for%20N-acetyltransferase%202&author=E.M.%20McDonagh&author=S.%20Boukouvala&author=E.%20Aklillu&author=D.W.%20Hein&author=R.B.%20Altman&volume=24&publication_year=2014&pages=409-425&pmid=24892773&doi=10.1097/FPC.0000000000000062&)

19. LiverTox . National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda: 2012. Clinical and Research Information on drug-induced liver injury.  [Google Scholar](https://scholar.google.com/scholar_lookup?LiverTox%20.%20National%20Institute%20of%20Diabetes%20and%20Digestive%20and%20Kidney%20Diseases;%20Bethesda:%202012.%20Clinical%20and%20Research%20Information%20on%20drug-induced%20liver%20injury.)

20. Nakai T., Sakai D., Nakamura Y., Horikita N., Matsushita E., Naiki M., et al. Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study. BMC Med Genomics. 2021;14:79. doi: 10.1186/s12920-021-00926-x.  [DOI](https://doi.org/10.1186/s12920-021-00926-x) | [PMC free article](/articles/PMC7948325/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/33706752/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMC%20Med%20Genomics&title=Association%20of%20NAT2%20genetic%20polymorphism%20with%20the%20efficacy%20of%20Neurotropin%C2%AE%20for%20the%20enhancement%20of%20aggrecan%20gene%20expression%20in%20nucleus%20pulposus%20cells:%20a%20pilot%20study&author=T.%20Nakai&author=D.%20Sakai&author=Y.%20Nakamura&author=N.%20Horikita&author=E.%20Matsushita&volume=14&publication_year=2021&pages=79&pmid=33706752&doi=10.1186/s12920-021-00926-x&)

21. Peetluk L.S., Ridolfi F.M., Rebeiro P.F., Liu D., Rolla V.C., Sterling TR. Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ Open. 2021;11 doi: 10.1136/bmjopen-2020-044687.  [DOI](https://doi.org/10.1136/bmjopen-2020-044687) | [PMC free article](/articles/PMC7929865/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/33653759/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ%20Open&title=Systematic%20review%20of%20prediction%20models%20for%20pulmonary%20tuberculosis%20treatment%20outcomes%20in%20adults&author=L.S.%20Peetluk&author=F.M.%20Ridolfi&author=P.F.%20Rebeiro&author=D.%20Liu&author=V.C.%20Rolla&volume=11&publication_year=2021&pmid=33653759&doi=10.1136/bmjopen-2020-044687&)

22. Chan S.L., Chua A.P.G., Aminkeng F., Chee C.B.E., Jin S., Loh M., et al. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS One. 2017;12 doi: 10.1371/journal.pone.0186200.  [DOI](https://doi.org/10.1371/journal.pone.0186200) | [PMC free article](/articles/PMC5642896/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/29036176/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS%20One&title=Association%20and%20clinical%20utility%20of%20NAT2%20in%20the%20prediction%20of%20isoniazid-induced%20liver%20injury%20in%20Singaporean%20patients&author=S.L.%20Chan&author=A.P.G.%20Chua&author=F.%20Aminkeng&author=C.B.E.%20Chee&author=S.%20Jin&volume=12&publication_year=2017&pmid=29036176&doi=10.1371/journal.pone.0186200&)

23. Prasad R., Singh A., Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc. 2019;66:520–532. doi: 10.1016/j.ijtb.2019.11.005.  [DOI](https://doi.org/10.1016/j.ijtb.2019.11.005) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/31813444/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Indian%20J%20Tuberc&title=Adverse%20drug%20reactions%20in%20tuberculosis%20and%20management&author=R.%20Prasad&author=A.%20Singh&author=N.%20Gupta&volume=66&publication_year=2019&pages=520-532&pmid=31813444&doi=10.1016/j.ijtb.2019.11.005&)

24. Wang P., Pradhan K., Zhong X.B., Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016;6:384–392. doi: 10.1016/j.apsb.2016.07.014.  [DOI](https://doi.org/10.1016/j.apsb.2016.07.014) | [PMC free article](/articles/PMC5045547/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/27709007/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Acta%20Pharm%20Sin%20B&title=Isoniazid%20metabolism%20and%20hepatotoxicity&author=P.%20Wang&author=K.%20Pradhan&author=X.B.%20Zhong&author=X.%20Ma&volume=6&publication_year=2016&pages=384-392&pmid=27709007&doi=10.1016/j.apsb.2016.07.014&)

25. Ramappa V., Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2013;3:37–49. doi: 10.1016/j.jceh.2012.12.001.  [DOI](https://doi.org/10.1016/j.jceh.2012.12.001) | [PMC free article](/articles/PMC3940184/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/25755470/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Exp%20Hepatol&title=Hepatotoxicity%20related%20to%20anti-tuberculosis%20drugs:%20mechanisms%20and%20management&author=V.%20Ramappa&author=GP.%20Aithal&volume=3&publication_year=2013&pages=37-49&pmid=25755470&doi=10.1016/j.jceh.2012.12.001&)

26. Zeleke A., Misiker B., Yesuf TA. Drug-induced hepatotoxicity among TB/HIV co-infected patients in a referral hospital, Ethiopia. BMC Res Notes. 2020;13:2. doi: 10.1186/s13104-019-4872-1.  [DOI](https://doi.org/10.1186/s13104-019-4872-1) | [PMC free article](/articles/PMC6941240/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/31898556/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMC%20Res%20Notes&title=Drug-induced%20hepatotoxicity%20among%20TB/HIV%20co-infected%20patients%20in%20a%20referral%20hospital,%20Ethiopia&author=A.%20Zeleke&author=B.%20Misiker&author=TA.%20Yesuf&volume=13&publication_year=2020&pages=2&pmid=31898556&doi=10.1186/s13104-019-4872-1&)

27. Kunst H., Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis. 2010;14:1374–1381.  [PubMed](https://pubmed.ncbi.nlm.nih.gov/20937175/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int%20J%20Tuberc%20Lung%20Dis&title=Age-related%20risk%20of%20hepatotoxicity%20in%20the%20treatment%20of%20latent%20tuberculosis%20infection:%20a%20systematic%20review&author=H.%20Kunst&author=KS.%20Khan&volume=14&publication_year=2010&pages=1374-1381&pmid=20937175&)

28. Becker M.W., Schwambach K.H., Lunardelli M., Blatt CR. Overview of drug induced liver injury in Brazil: what is the role of public health policy on the evidence? World J Gastrointest Pharmacol Ther. 2021;12:40–55. doi: 10.4292/wjgpt.v12.i3.40.  [DOI](https://doi.org/10.4292/wjgpt.v12.i3.40) | [PMC free article](/articles/PMC8134851/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/34046243/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=World%20J%20Gastrointest%20Pharmacol%20Ther&title=Overview%20of%20drug%20induced%20liver%20injury%20in%20Brazil:%20what%20is%20the%20role%20of%20public%20health%20policy%20on%20the%20evidence?&author=M.W.%20Becker&author=K.H.%20Schwambach&author=M.%20Lunardelli&author=CR.%20Blatt&volume=12&publication_year=2021&pages=40-55&pmid=34046243&doi=10.4292/wjgpt.v12.i3.40&)

29. Deribew A., Deribe K., Dejene T., Tessema G.A., Melaku Y.A., Lakew Y., et al. Tuberculosis burden in Ethiopia from 1990 to 2016: evidence from the global burden of diseases 2016 study. Ethiop J Health Sci. 2018;28:519–528. doi: 10.4314/ejhs.v28i5.2.  [DOI](https://doi.org/10.4314/ejhs.v28i5.2) | [PMC free article](/articles/PMC6308773/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/30607066/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ethiop%20J%20Health%20Sci&title=Tuberculosis%20burden%20in%20Ethiopia%20from%201990%20to%202016:%20evidence%20from%20the%20global%20burden%20of%20diseases%202016%20study&author=A.%20Deribew&author=K.%20Deribe&author=T.%20Dejene&author=G.A.%20Tessema&author=Y.A.%20Melaku&volume=28&publication_year=2018&pages=519-528&pmid=30607066&doi=10.4314/ejhs.v28i5.2&)

30. Devarbhavi H., Aithal G., Treeprasertsuk S., Takikawa H., Mao Y., Shasthry S.M., et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int. 2021;15:258–282. doi: 10.1007/s12072-021-10144-3.  [DOI](https://doi.org/10.1007/s12072-021-10144-3) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/33641080/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Hepatol%20Int&title=Drug-induced%20liver%20injury:%20Asia%20Pacific%20Association%20of%20Study%20of%20Liver%20consensus%20guidelines&author=H.%20Devarbhavi&author=G.%20Aithal&author=S.%20Treeprasertsuk&author=H.%20Takikawa&author=Y.%20Mao&volume=15&publication_year=2021&pages=258-282&pmid=33641080&doi=10.1007/s12072-021-10144-3&)
